Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (SCCLG-M5)

Sun Yat-sen University logo

Sun Yat-sen University

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Leukemia, Monocytic, Acute
Pediatric AML

Treatments

Drug: Idarubicin
Drug: Cytarabine
Drug: Sorafenib
Drug: Cladribine
Drug: Mitoxantrone
Drug: G-CSF

Study type

Interventional

Funder types

Other

Identifiers

NCT05313958
2021-KY-052
2021A1515011809 (Other Grant/Funding Number)

Details and patient eligibility

About

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period for the treatment of newly dignosed acute monocytic leukemia (M5). The targeted drugs sorafenib is used for FLT3 positive acute monocytic leukemia to inhibit the serine / threonine kinase activity of FLT3.

Full description

PRIMARY OBJECTIVES 1.To study the 3 year-overall survival of newly diagnosed monocytic leukemia treated with Cladribine and cytarabine in children. SECONDARY OBJECTIVES To describe the complete response rate following CLAG (cladribine, cytarabine and granulocyte stimulating factor) in newly diagnosed monocytic leukemia in children for intensive induction therapy. To evaluate the 3-year progression-free survival in response to CLAG in children. To assess the toxicity of CLAG including cumulative infection incidence, cumulative adverse effects and chemotherapy-related mortality (TRD). To study the progression-free survival and overall survival (1 year, 2 year and 3 year) of newly diagnosed monocytic leukemia with positive FLT3 treated with CLAG in children and the side effects of sorafenib. OUTLINE: The induction phase includes two parts including induction therapy I(CLAG) and induction therpay II(CLAG+I/M). The diagnosis and classified criteria is according to the 2016 WHO classification criteria for hematopoietic and lymphoid tissue tumors, and the consolidation therapy consists the therapeutic phases as the NOPHO-AML 2004 protocol prescribed. INDUCTION THERAPY I: Patients receive cladribine intravenously (IV) at a dose of 5mg/m2/day combined with cytarabine 2g/m2/day on day 1-5 and granulocyte stimulating factor 5ug/kg/day on day 0-6. When blood count recover(WBC>2.0×109/L, ANC1.0×109/L、PLT≥50×109/L) , Patients achieving a morphological leukemia free state (< 5% blasts) or MRD< 1% receive a second course treatment as above. INDUCTION THERPAY II: Patients receive cladribine intravenously (IV) at a dose of 5mg/m2/day combined with cytarabine 2g/m2/day on day 1-5, mitoxantrone/idarubicin 10mg/m2/day on day 1-3 and granulocyte stimulating factor 5ug/kg/day on day 0-6. Patients achieving blast count≥5% or MRD ≥1% proceed to induction II therpy. For FLT3 positive acute monocytic leukemia children, sorafenib 200mg/m2/day was taken orally until molecular biology remission for 2 years. After two courses of indution phase, patients with incomplete response(MRD≥0.1%)are recommended into hematopoietic stem cell transplantation. After two courses of indution phase, patients with persisting positive adverse prognosis cytogenetic abnormalities are recommended into hematopoietic stem cell transplantation. Patients must meet one of the following risk criteria: Standard-risk (SR) group meeting all of the following criteria: Initial WBC < 10,000/μL M1 (<5%) blasts or MRD<1% in bone marrow after the first course of induction therapy M1 (<5%) blasts or MRD<0.1% in bone marrow after two courses of induction therapy Cytogenetic abnormalities with good prognosis Intermediate-risk (IR) group meeting the following criteria: Lack of low-risk and high-risk conditions High-risk (HR) group meeting ≥ 1 of the following criteria: M2/M3(≥5%) blasts or MRD>5% in bone marrow after the first course of induction therapy MRD≥0.1% in bone marrow after two course of induction therapy Cytogenetic abnormalities with poor prognosis

Enrollment

43 estimated patients

Sex

All

Ages

1 month to 14 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

0-14 years old

Cytologically proven acute monocytic leukemia (M5) with other treatment

Exclusion criteria

Secondary to immunodeficiency or MDS

Second tumor

Dowm's syndrome

Evolution of chronic myelogenous leukemia to blast crisis

Death or quit treatment in seven days at the begining of induction therapy

Treatment with other effective chemotherapy drugs for AML, excluding the low dose chemotherapy for the purpose of reducing leukocytes in hyperleukocytic leukemia

Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled heart, brain, liver and kidney failure etc.)

Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

43 participants in 1 patient group

treatment arm
Experimental group
Description:
The patients in this arm will receive SCCLG-M5 2022 regimen for newly dignosed acute monocytic leukemia (M5) ,including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period and followed by three courses(HA1M, HA2E, HA3) in consolidation therapy prescribed as the NOPHO-AML 2004 protocol. The targeted drugs sorafenib 200mg/m2/day orally is used for FLT3 positive acute monocytic leukemia until molecular biology remission for 2 years.
Treatment:
Drug: Mitoxantrone
Drug: G-CSF
Drug: Cladribine
Drug: Sorafenib
Drug: Cytarabine
Drug: Idarubicin

Trial contacts and locations

9

Loading...

Central trial contact

dunhua zhou, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems